Regeneron (REGN - Free Report) reported $3.43 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 0.6%. EPS of $11.86 for the same period compares to $12.56 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $3.26 billion, representing a surprise of +5.37%. The company delivered an EPS surprise of +13.71%, with the consensus EPS estimate being $10.43.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Eylea (Aflibercept)- US: $1.34 billion compared to the $1.45 billion average estimate based on five analysts. The reported number represents a change of -10.6% year over year.
- Revenues- Praluent (alirocumab)- US: $61.30 million versus $41.83 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +72.7% change.
- Revenues- Kevzara (sarilumab)- ROW: $46 million compared to the $40.80 million average estimate based on four analysts. The reported number represents a change of +33% year over year.
- Revenues- Dupixent (dupilumab)- US: $2.49 billion compared to the $2.43 billion average estimate based on four analysts. The reported number represents a change of +28.4% year over year.
- Revenues- Net product sales: $1.85 billion compared to the $1.82 billion average estimate based on seven analysts. The reported number represents a change of +9% year over year.
- Revenues- Collaboration: $1.37 billion compared to the $1.35 billion average estimate based on seven analysts. The reported number represents a change of -13.7% year over year.
- Revenues- Other Revenue: $212.50 million compared to the $122.32 million average estimate based on six analysts. The reported number represents a change of +66.4% year over year.
- Revenues- Dupixent (dupilumab)- Total: $3.22 billion compared to the $3.13 billion average estimate based on four analysts. The reported number represents a change of +31.3% year over year.
- Revenues- Libtayo- Total: $243.80 million versus the four-analyst average estimate of $252.01 million. The reported number represents a year-over-year change of +44.4%.
- Revenues- Eylea (Aflibercept)- Total: $2.23 billion compared to the $2.35 billion average estimate based on four analysts. The reported number represents a change of -4.6% year over year.
- Revenues- Kevzara (sarilumab)- Total: $112.20 million versus $91.81 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +38.2% change.
- Revenues- Praluent (alirocumab)- Total: $187.20 million versus the four-analyst average estimate of $151.57 million. The reported number represents a year-over-year change of +40.3%.
View all Key Company Metrics for Regeneron here>>>Shares of Regeneron have returned +5% over the past month versus the Zacks S&P 500 composite's +2.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Regeneron (REGN - Free Report) reported $3.43 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 0.6%. EPS of $11.86 for the same period compares to $12.56 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $3.26 billion, representing a surprise of +5.37%. The company delivered an EPS surprise of +13.71%, with the consensus EPS estimate being $10.43.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Eylea (Aflibercept)- US: $1.34 billion compared to the $1.45 billion average estimate based on five analysts. The reported number represents a change of -10.6% year over year.
- Revenues- Praluent (alirocumab)- US: $61.30 million versus $41.83 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +72.7% change.
- Revenues- Kevzara (sarilumab)- ROW: $46 million compared to the $40.80 million average estimate based on four analysts. The reported number represents a change of +33% year over year.
- Revenues- Dupixent (dupilumab)- US: $2.49 billion compared to the $2.43 billion average estimate based on four analysts. The reported number represents a change of +28.4% year over year.
- Revenues- Net product sales: $1.85 billion compared to the $1.82 billion average estimate based on seven analysts. The reported number represents a change of +9% year over year.
- Revenues- Collaboration: $1.37 billion compared to the $1.35 billion average estimate based on seven analysts. The reported number represents a change of -13.7% year over year.
- Revenues- Other Revenue: $212.50 million compared to the $122.32 million average estimate based on six analysts. The reported number represents a change of +66.4% year over year.
- Revenues- Dupixent (dupilumab)- Total: $3.22 billion compared to the $3.13 billion average estimate based on four analysts. The reported number represents a change of +31.3% year over year.
- Revenues- Libtayo- Total: $243.80 million versus the four-analyst average estimate of $252.01 million. The reported number represents a year-over-year change of +44.4%.
- Revenues- Eylea (Aflibercept)- Total: $2.23 billion compared to the $2.35 billion average estimate based on four analysts. The reported number represents a change of -4.6% year over year.
- Revenues- Kevzara (sarilumab)- Total: $112.20 million versus $91.81 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +38.2% change.
- Revenues- Praluent (alirocumab)- Total: $187.20 million versus the four-analyst average estimate of $151.57 million. The reported number represents a year-over-year change of +40.3%.
View all Key Company Metrics for Regeneron here>>>Shares of Regeneron have returned +5% over the past month versus the Zacks S&P 500 composite's +2.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Get the latest research report on REGN - FREE